Efficacy of oral mefenamic acid in treatment of rash of Gianotti–Crosti syndrome: A prospective noncontrolled case-series study

Usama Abdul-Jaleel*

Abstract

Background: Gianotti–Crosti syndrome (GCS) is a characteristic cutaneous response to viral & non-viral infection mainly affecting children. No treatment appears to shorten the course of the disease which lasts 3-8 weeks. Mefenamic acid is NSAID which acts as competitive inhibitor of prostaglandin biosynthesis.

Objective: To assess the efficacy and safety of oral mefenamic acid 50 mg twice a day in the treatment of (GCS) for 10 days

Methods: In this prospective non-controlled case series study, 36 patients were identified as having Gianotti–Crosti syndrome by dermatologist in Al-Diwanya Teaching Hospital, from January 2012 to May 2013 and they have been treated with oral mefenamic acid 50 mg twice a day for 10 days.

*Department of Dermatology, Al-Qadissiya College of Medicine Al-Diwanya, Iraq.
Results: 36 patients entered the current study. The mean age of the patients was 21.2 (1 - 5.5) years. There were 19 (52.8%) females and 17 (47.2%) males. Complete clearance of the rash of GCS at all sites was seen in 33 patients (91.6%) within 10 days of initiation of the therapy, leaving the skin with fine desquamation (P<0.05). Two patients experienced no change in the rash until after 3 weeks it got resolution of the rash and one patient got his rash resolved after one month. None of the patients suffered adverse effects during the usage of treatment and the period of the follow-up.

Conclusion: oral mefenamic acid seems to be effective in treatment of Gianotti–Crosti syndrome

Key words: Gianotti–Crosti syndrome, mefenamic acid

Introduction

Gianotti–Crosti syndrome is a characteristic cutaneous response to viral infection (1,2,3). The majority of the earliest reported cases had hepatitis B infection, but several other viruses and even non-viral infections have been associated. The most common of these is EBV (4,5). Infrequently reported, and therefore of less certain significance, are coxsackie A16 (6), coxsackie B4 and B5 [5], echovirus 7 (7), echovirus 9 (8), poliovirus (9), CMV (5), HHV6 (10), respiratory syncytial virus (9), parainfluenza virus (3), hepatitis A (11), parvovirus B19 (8), milker’s nodules (13) and HIV (14). Non-viral associations are Mycoplasma pneumoniae and β-haemolytic streptococci (9,15). Occasional cases following immunization, for example combined measles, mumps, rubella vaccine (16), diphtheria, pertussis and influenza (5,17) and hepatitis A (18) or B (19) are of uncertain significance. In a minority of cases, no evidence of viral infection can be found. The syndrome mainly affects children between the ages of 6 months and 12 years, though occasional adult female cases have occurred (20,21). Pathology: The skin lesions show slight or moderate acanthosis and hyperkeratosis. In the edematous upper dermis an infiltrate of lymphocytes and histiocytes surrounds dilated capillaries. The lymph nodes show a diffuse reticulum-cell
hyperplasia, often of severe degree. Clinical features\(^{(1,22)}\). Over the course of 3 or 4 days a profuse eruption of dull red flat-topped papules develops first on the thighs and buttocks, then on the extensor aspects of the arms, and finally on the face. In the hepatitis B cases, liver involvement appears to be invariable, usually mild and anicteric, but occasionally there is jaundice, and histological recovery may take between 6 months and 4 years.

Treatment: There is no specific treatment. Emollients and topical steroids may help to relieve pruritus. However, spontaneous resolution usually occurs within 3–8 weeks\(^{(24)}\). No treatment appears to shorten the course of the disease\(^{(25)}\).

Mefenamic acid is a non-steroidal anti-inflammatory drug which a competitive inhibitor of COX-1 and COX-2, which are responsible for the first committed step in prostaglandin biosynthesis. Decreasing the activity of these enzymes thus reduces the production of prostaglandins, which are implicated in inflammation process.

**Aim of the study**

To assess the efficacy and safety of oral mefenamic acid 50 mg twice a day in the treatment of Gianotti–Crosti syndrome.

**Patients and methods**

**Study design:**

Open labeled (prospective uncontrolled) therapeutic trial was done on 36 outpatients seeking treatment for Gianotti–Crosti syndrome were assessed by dermatologist in the outpatient clinic of the Department of Dermatology in Al-Diwanyia Teaching Hospital, Diwanyia, Iraq, from January 2012 to May 2013. This study was in agreement with the ethics of Al-Diwanyia Teaching Hospital.

**Patients**

The patients were diagnosed clinically by a dermatologist in Al-Diwanyia Teaching Hospital as Gianotti–Crosti syndrome. Questions covered age, sex. All patients started on oral mefenamic acid 50 mg twice daily for 10 days.
Evaluations

‘Evaluation of clinical symptoms and complaints pretreatment and after initiation of treatment with oral mefenamic acid

The evaluation was performed by same dermatologist at day 0, 10 and 30 after the initiation of the treatment with oral mefenamic acid.

Results

36 patients entered the current study. The mean age of the patients was 2 ± 1.2 (1-5) years. There were 19 (52.8%) females and 17 (47.2%) males.

All the patients complained of pruritus but with variable severity. Figure(1) and(2) showed that treatment with oral mefenamic acid had lead to cause complete clearance of the rash of GC at all sites in 33 patients (91.6%) within 10 days of initiation of the therapy, leaving the skin with fine desquamation (P<0.05). Two patients experienced no change in the rash until after 3 weeks it got resolution of the rash and one patient get his rash resolved after one month. Subsequent follow-up to 8 weeks did not show any recurrence of the rash. None of the patients noticed adverse effects during the usage of treatment and the period of the follow-up.

Fig .(1) The effects of mefenamic acid 50mg twice daily (in day 0, day, 10 day 30) on the number patients with rash of Gianotti–Crosti syndrome.
Fig. (2) showed patient with Gianotti–Crosti syndrome before treatment (A) and after 10 days treatment with mefenamic acid (B)

Discussion
Although the treatment for Gianotti–Crosti syndrome is supportive and the prognosis is good with spontaneous resolution, it usually takes 3-4 weeks and may persist for up to 8 weeks (24). Taking into consideration that the parents got concerned about this "unusually prolonged symptomatic rash". No treatment appears to shorten the course of the disease (25). Mefenamic acid is a non-steroidal anti-inflammatory drug which is a competitive inhibitor of COX-1 and COX-2, which are responsible for the first committed step in prostaglandin biosynthesis. In the current study, the results showed that mefenamic acid might be able to shorten the course of the rash of the disease. Clearance
of the rash can not be attributed to the natural history of the
disease espacially when the majority of the patients had got
improved within approximately equal time i.e. 10 days .The rash of
this disease usually takes variably prolonged duration.The
mechanism of action of this drug is unknown and probably through
its anti-inflammatory effect and we recommend to search for its
effect through a further proper study.

Conclusions
From this study, one can conclude that mefenamic acid therapy in
oral form may be able to shorten the course of the rash the
disease .
Drawbacks of this study were.(1) Lack of a control group ,(2) the
study did not reveal the mechanism by which mefenamic acid
affected the rash (3) Limited follow-up of the patients.

References
1 Brandt O, Abeck D, Gianotti R et al. Gianotti–Crosti syndrome.
2 Crosti A, Gianotti F. Dermatose eruptive acro-situeé
d’origine probablement virosique. Dermatologica 1957; 115: 671–
7.
3 Spear KL, Winkelmann RK. Gianotti–Crosti syndrome. A
review of ten cases not associated with hepatitis B. Arch Dermatol
1984; 120: 891–6.
4 Drago F, Crovato F, Rebora A. Gianotti–Crosti syndrome as a
presenting sign of EBV-induced acute infectious mononucleosis.
6 James WD, Odom RB, Hatch MH. Gianotti–Crosti-like eruption
associated with coxsackievirus A-16 infection. J Am Acad
7 Labbe A, Peyrot J, Goumy P et al. Syndrome
acropapulovesiculeux de l’enfant quatre observations d’étiologie